Medivir has announced positive results from a Phase IIb study of TMC435 in patients with genotype 1 chronic hepatitis C.

The randomised, placebo-controlled, double-blind study included 462 patients who have relapsed, achieved partial response, or achieved no response to standard of care treatment.

Interim 48-week data revealed that 94% of patients treated with TMC435 showed sustained virologic response, compared to 84% for placebo.

TMC435 treated patients achieved undetectable HCV RNA levels, mild and reversible increases in bilirubin and decrease in mean alanine aminotransferase levels.

The adverse affects seen during the treatment period were headache, fatigue, pruritus and influenza-like illness.